Natalia Elizalde discusses the evolving manufacturing landscape for gene therapies in BioSpectrum Asia
The interview explores the growing demand for lentiviral vectors, the manufacturing requirements associated with emerging in vivo applications, and the innovation needed to support the next generation of gene therapies.
VIVEbiotech is pleased to share that BioSpectrum Asia has published an exclusive interview with Natalia Elizalde, Chief Business Development Officer at VIVEbiotech, examining the trends, challenges, and opportunities shaping the future of viral vector manufacturing.
In the interview, Natalia discusses how growing interest in in vivo gene therapy is bringing new considerations for manufacturing, including scalability, product quality, analytical characterization, and process efficiency. As gene therapy programmes continue to advance, manufacturing is playing an increasingly strategic role in supporting successful clinical and commercial development.
The conversation also highlights the continued importance of lentiviral vectors across the broader gene therapy landscape. While established ex vivo applications continue to drive demand for lentiviral vectors, emerging in vivo approaches are introducing new manufacturing requirements related to scale, analytics and process performance.
Among the topics addressed are the technical and operational considerations associated with supporting different therapeutic approaches, the importance of robust process development and analytical capabilities, and the innovation required to meet the evolving needs of developers worldwide.
As VIVEbiotech continues to strengthen collaborations across international markets, including Asia, we are proud to contribute to the global conversation on the future of lentiviral vector manufacturing and the advancement of innovative therapies.
With a strong track record in ex vivo gene therapy programmes and experience supporting more than 15 in vivo programmes to date, including two already in clinical development, VIVEbiotech is well positioned to support developers across the evolving gene therapy landscape through robust and scalable lentiviral vector manufacturing solutions.
Read the full interview: BioSpectrum Asia – The Manufacturing Shift Powering In Vivo Gene Therapy
